Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Rapport Therapeutics, Inc. (RAPP) had Return on Tangible Equity of -10.14% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-26.73M |
|
-- |
|
-- |
|
$29.50M |
|
$-29.50M |
|
$2.76M |
|
$-26.73M |
|
$-26.73M |
|
$-26.73M |
|
$-26.73M |
|
$-26.73M |
|
$-26.73M |
|
$-29.50M |
|
$-29.34M |
|
35.45M |
|
35.45M |
|
$-0.75 |
|
$-0.75 |
|
| Balance Sheet Financials | |
$270.24M |
|
$3.17M |
|
$15.25M |
|
$285.50M |
|
$11.88M |
|
-- |
|
$10.10M |
|
$21.98M |
|
$263.51M |
|
$263.51M |
|
$263.51M |
|
36.50M |
|
| Cash Flow Statement Financials | |
$-45.31M |
|
$43.63M |
|
$-0.06M |
|
$56.91M |
|
$55.17M |
|
$-1.74M |
|
$8.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
22.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-45.62M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.14% |
|
|
Return on Tangible Equity |
-10.14% |
-9.36% |
|
-10.14% |
|
$7.22 |
|
$-1.29 |
|
$-1.28 |
|